David A Reardon Selected Research

Cilengitide

5/2018	Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?
3/2016	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
5/2015	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
11/2014	Antiangiogenic therapy for glioblastoma: current status and future prospects.
9/2014	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
12/2011	Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies.
3/2011	Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.
12/2008	Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
8/2008	Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David A Reardon Research Topics

Disease

159	Glioblastoma (Glioblastoma Multiforme) 11/2022 - 01/2004
147	Neoplasms (Cancer) 05/2022 - 05/2002
89	Glioma (Gliomas) 01/2021 - 03/2002
41	Brain Neoplasms (Brain Tumor) 01/2022 - 10/2003
10	Meningioma (Meningiomas) 01/2022 - 01/2012
9	Melanoma (Melanoma, Malignant) 12/2021 - 04/2006
9	Fatigue 10/2019 - 12/2010
8	Disease Progression 12/2021 - 01/2012
6	Diarrhea 01/2018 - 01/2004
5	Astrocytoma (Pilocytic Astrocytoma) 10/2019 - 01/2006
5	Hemorrhage 01/2018 - 10/2009
5	Lymphopenia (Lymphocytopenia) 09/2014 - 06/2010
4	Oligodendroglioma 05/2022 - 01/2006
4	Residual Neoplasm 10/2019 - 11/2010
4	Thrombocytopenia (Thrombopenia) 09/2014 - 04/2003
3	Hypoxia (Hypoxemia) 01/2021 - 12/2010
3	Neoplasm Metastasis (Metastasis) 01/2021 - 08/2018
3	Edema (Dropsy) 01/2021 - 02/2017
3	Gliosarcoma 01/2020 - 01/2006
3	Hypertension (High Blood Pressure) 10/2019 - 01/2013
3	Lymphoma (Lymphomas) 01/2014 - 01/2013

Drug/Important Bio-Agent (IBA)

57	Temozolomide (Temodar)FDA LinkGeneric 11/2022 - 02/2003
52	Bevacizumab (Avastin)FDA Link 01/2021 - 02/2007
28	ErbB Receptors (EGF Receptor)IBA 01/2022 - 01/2004
20	Monoclonal AntibodiesIBA 11/2017 - 03/2002
18	Immune Checkpoint InhibitorsIBA 11/2022 - 09/2015
18	VaccinesIBA 01/2021 - 05/2008
18	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 02/2008
18	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 05/2003
16	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2011
15	epidermal growth factor receptor VIIIIBA 01/2022 - 10/2009
13	NivolumabIBA 11/2022 - 09/2015
13	Pharmaceutical PreparationsIBA 11/2020 - 08/2010
11	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2021 - 04/2010
11	Tyrosine Kinase InhibitorsIBA 01/2018 - 01/2004
10	Proteins (Proteins, Gene)FDA Link 01/2021 - 04/2006
9	AntigensIBA 01/2020 - 09/2004
9	CilengitideIBA 05/2018 - 08/2008
8	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2021 - 01/2017
8	Phosphotransferases (Kinase)IBA 11/2019 - 01/2005
8	IntegrinsIBA 05/2018 - 08/2008
7	TOR Serine-Threonine KinasesIBA 11/2019 - 01/2005
7	Angiogenesis InhibitorsIBA 06/2017 - 04/2010
7	Carmustine (FIVB)FDA Link 11/2014 - 05/2002
6	IpilimumabIBA 12/2021 - 09/2015
6	pembrolizumabIBA 01/2021 - 09/2015
6	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2018 - 01/2005
6	EnzymesIBA 02/2013 - 02/2006
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 11/2012 - 01/2010
6	Imatinib Mesylate (Gleevec)FDA Link 10/2012 - 12/2005
6	O(6)-benzylguanineIBA 10/2009 - 05/2002
5	B7-H1 AntigenIBA 01/2022 - 03/2015
5	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 11/2017
5	DNA (Deoxyribonucleic Acid)IBA 05/2018 - 05/2008
5	Biological ProductsIBA 01/2017 - 01/2012
5	Anticonvulsants (Antiepileptic Drugs)IBA 03/2016 - 02/2006
5	Hydroxyurea (Hydrea)FDA LinkGeneric 10/2012 - 12/2005
5	Peptides (Polypeptides)IBA 01/2012 - 05/2008
4	Lomustine (CCNU)FDA Link 05/2022 - 11/2014
4	LigandsIBA 01/2021 - 02/2016
4	CytokinesIBA 01/2021 - 01/2012
4	InterferonsIBA 01/2020 - 01/2018
4	AntibodiesIBA 10/2018 - 02/2016
4	MethyltransferasesIBA 05/2018 - 08/2013
4	cabozantinibIBA 01/2018 - 02/2016
4	Cytotoxins (Cytolysins)IBA 11/2015 - 02/2007
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2012 - 11/2005
4	Immunotoxins (Immunotoxin)IBA 09/2011 - 01/2005
3	AfatinibIBA 01/2022 - 03/2015
3	RNA (Ribonucleic Acid)IBA 01/2021 - 03/2015
3	SteroidsIBA 01/2021 - 01/2005
3	rindopepimutIBA 01/2020 - 01/2015
3	EpitopesIBA 01/2019 - 01/2018
3	Immunoconjugates (Immunoconjugate)IBA 01/2019 - 07/2017
3	Carboplatin (JM8)FDA LinkGeneric 01/2019 - 12/2011
3	depatuxizumab mafodotinIBA 01/2019 - 12/2017
3	Messenger RNA (mRNA)IBA 11/2016 - 04/2006
3	O(6)-Methylguanine-DNA MethyltransferaseIBA 05/2015 - 05/2002
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2015 - 02/2006
3	Alkylating AgentsIBA 08/2013 - 05/2003
3	Sirolimus (Rapamycin)FDA Link 11/2012 - 02/2006
3	AEE 788 (AEE788)IBA 06/2012 - 01/2005
3	Adenosine Triphosphate (ATP)IBA 05/2012 - 12/2005
3	Everolimus FDA Link 01/2012 - 01/2005
3	Human Serum Albumin FDA LinkGeneric 09/2011 - 03/2007
3	Topoisomerase I InhibitorsIBA 10/2005 - 04/2004
2	Procarbazine (Matulane)FDA Link 05/2022 - 12/2017
2	Vincristine (Oncovin)FDA LinkGeneric 05/2022 - 12/2017
2	Interleukin-12 (IL 12)IBA 01/2022 - 01/2019

Therapy/Procedure

105	Therapeutics 01/2022 - 01/2005
42	Immunotherapy 01/2022 - 09/2004
37	Radiotherapy 11/2022 - 06/2005
30	Drug Therapy (Chemotherapy) 05/2022 - 04/2003
7	Chemoradiotherapy 11/2022 - 04/2010
7	Salvage Therapy 10/2018 - 02/2007
4	Radioimmunotherapy 05/2007 - 09/2005
3	Molecular Targeted Therapy 01/2021 - 02/2015
3	Drug Tapering 01/2018 - 01/2012
3	Re-Irradiation 12/2017 - 07/2016
3	Brachytherapy 09/2015 - 01/2006